Oxymatrine exerts its anti-angiogenic effect in pancreatic cancer cells via targeting the NF-κB pathway and hindering the activity of the vascular endothelial growth factor (VEGF) involved in stimulating vasculogenesis and angiogenesis [89]. Here, VEGFA is linked to familial pancreatic carcinoma.